News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

Once-a-day insulin subsidised for NZ patients

Once-a-day insulin subsidised for NZ patients

A type of insulin for people with diabetes that requires only one injection a day will be funded from 1 July, PHARMAC announced today.

Insulin glargine (Lantus) is a long-acting type of insulin that will be funded for people who have the most difficulty controlling their blood sugar levels. This is an advancement for diabetes patients, as insulin glargine can reduce the risk of hypoglycaemia for some patients.

PHARMAC’s Chief Executive Wayne McNee says funding of a true long-acting insulin is a step forward for the subsidised treatment of diabetes. About 30,000 New Zealanders with diabetes use insulin, either on its own or in combination with other diabetes treatments.

“This decision extends the range of subsidised treatments for New Zealanders with diabetes,” Wayne McNee says.

“Most people achieve glycaemic control with the insulins that are currently funded, and we currently spend about $19 million per year on diabetes treatments, with a further $20 million spent on test strips.”

“However, we are aware that there is a group of patients who could benefit from a longer-acting product, so we are pleased to make an investment that extends funding to insulin glargine.”

Wayne McNee says the criteria for subsidising insulin glargine would see about 3200 patients using the treatment within three years. This would represent about 10% of all people currently using insulin.

PHARMAC estimates that insulin glargine will see further expenditure of more than $5 million over the next five years.

[ends]


© Scoop Media

 
 
 
Culture Headlines | Health Headlines | Education Headlines

 
Legendary Bassist David Friesen Plays Wellington’s Newest Jazz Venue

Friesen is touring New Zealand to promote his latest album Another Time, Another Place, recorded live at Auckland's Creative Jazz Club in 2015. More>>

Howard Davis Review: The Father - Descending Into The Depths of Dementia

Florian Zeller's dazzling drama The Father explores the effects of a deeply unsettling illness that affects 62,000 Kiwis, a number expected to grow to 102,000 by 2030. More>>


Howard Davis Review: Blade Runner Redivivus

When Ridley Scott's innovative, neo-noir, sci-fi flick Blade Runner was originally released in 1982, at a cost of over $45 million, it was a commercial bomb. More>>

14-21 October: New Zealand Improv Festival In Wellington

Imagined curses, Shibuya’s traffic, the apocalypse, and motherhood have little in common, but all these and more serve as inspiration for the eclectic improvised offerings coming to BATS Theatre this October for the annual New Zealand Improv Festival. More>>

ALSO:

Bird Of The Year Off To A Flying Start

The competition asks New Zealanders to vote for their favourite bird in the hopes of raising awareness of the threats they face. More>>

Scoop Review Of Books:
Jenny Abrahamson's John & Charles Enys: Castle Hill Runholders, 1864-1891

This volume will be of interest to a range of readers interested in the South Island high country, New Zealand’s natural environment, and the history of science. More>>

 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION